Covaxin has been approved by the Drugs Controller General of India (DCGI), for Phase 2-3 clinical trials in the age group of 2 to 18 years. The Phase 2-3 clinical trials of COVID-19 vaccine, Covaxin, which has been approved by the Drugs Controller General of India (DCGI), for in the age group of 2 to 18 years, will begin in 10 to 12 days. Also read DCGI approves Covaxin clinical trials for children aged 2-18 yearsThis is the first time in India that a COVID-19 vaccine will be tested on children. The clinical trials involve two COVID-19 vaccine shots injected on day 0 and day 28. Hyderabad-based Bharat Biotech had proposed to carry out the clinical trial in the age group of 2 to 18 years.

Source: dna May 18, 2021 13:07 UTC